Natera, Inc.(NTRA)Earnings, Financials & Key RatiosNatera, Inc. (NTRA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a robust $1.1 billion cash balance and improving gross margins, the persistent negative operating income of $93.5 million in 2026Q1 suggests that achieving consistent profitability remains a significant hurdle.
Natera, Inc. (NTRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Natera, Inc. (NTRA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.56vs $0.54-3.3% | $697Mvs $617M+12.9% |
| Q1 2026 | Feb 26, 2026 | $0.35vs $0.51+168.3% | $666Mvs $604M+10.2% |
| Q4 2025 | Nov 6, 2025 | $0.64vs $0.39-65.9% | $592Mvs $513M+15.3% |
| Q3 2025 | Aug 7, 2025 | $0.74vs $0.62-20.2% | $547Mvs $476M+14.8% |
Recent stock market news and headlines for Natera, Inc. (NTRA)
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta's global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).APG.
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial of tegoprubart, an in.
Key metrics vs top competitors for Natera, Inc. (NTRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $281.27 | $40.28B | -185.05 | 35.9% | -9.03% | -14.32% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $2.39 | $225.98M | 6.29 | 161.14% | 48.57% | 55.68% | — | |
| $419.08 | $6.53B | 55.65 | 8.79% | 3.71% | 22.14% | — | |
| $1.56 | $484.54M | -0.86 | 3.89% | -80.34% | -488.45% | — |
Natera, Inc. (NTRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Natera, Inc. (NTRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 1, 2026·SEC
Feb 26, 2026·SEC
Feb 27, 2026·SEC
Get notified when NTRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Natera, Inc. (NTRA) stock FAQ — growth, dividends, profitability & financials explained
Natera, Inc. (NTRA) reported $2.50B in revenue for fiscal year 2025. This represents a 17450% increase from $14.3M in 2012.
Natera, Inc. (NTRA) grew revenue by 35.9% over the past year. This is strong growth.
Natera, Inc. (NTRA) reported a net loss of $226.3M for fiscal year 2025.
Natera, Inc. (NTRA) has a return on equity (ROE) of -14.3%. Negative ROE indicates the company is unprofitable.
Natera, Inc. (NTRA) generated $92.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
